Consolidated Financial Results for the 1st Quarter and Full‐Year Forecasts for Fiscal 2022

from the beginning

Consolidated Financial Results for the 1st Quarter and Full‐Year Forecasts for Fiscal 2022

Disclaimer

Highlights

• 01. Consolidated Financial Results and Business Review for the 1Q of Fiscal 2022 (FY Ending March 31, 2022)

1Q of Fiscal 2022 (1) Consolidated Financial Results

Composition of Each Division : Sub‐segments

1Q of FY2022 (2) Endoscopic Solutions Division (ESD)

1Q of FY2022 (3) Therapeutic Solutions Division (TSD)

1Q of FY2022 (4) Scientific Solutions Division (SSD)

Statement of Financial Position

Consolidated Cash Flows

• 02. Forecasts for Fiscal 2022

Fiscal 2022 Consolidated Forecasts

Fiscal 2022 Forecasts by Business Segment

• 03. Transforming into a Truly Global Medtech Company

Key Product Catalysts: Endoscopic Solutions Division (As of Aug 5, 2021)

Key Product Catalysts: Therapeutic Solutions Division (As of Aug 5, 2021)

FY2022 Key Initiatives

@

@

Appendix

1Q of Fiscal 2022 Factors that Affected Consolidated Operating Profit

1Q of Fiscal 2022 by Segment

Expenditures, etc.

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8

• Q&A 9

• Q&A 10